Share-based Payment Arrangement, Expense of FATE THERAPEUTICS INC from 31 Dec 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
FATE THERAPEUTICS INC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2011 to 31 Dec 2025.
  • FATE THERAPEUTICS INC Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $5,528,000, a 39% decline year-over-year.
  • FATE THERAPEUTICS INC Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $24,924,000, a 40% decline year-over-year.
  • FATE THERAPEUTICS INC annual Share-based Payment Arrangement, Expense for 2025 was $24,924,000, a 40% decline from 2024.
  • FATE THERAPEUTICS INC annual Share-based Payment Arrangement, Expense for 2024 was $41,496,000, a 4.5% decline from 2023.
  • FATE THERAPEUTICS INC annual Share-based Payment Arrangement, Expense for 2023 was $43,459,000, a 45% decline from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

FATE THERAPEUTICS INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $24,924,000 $5,528,000 -$3,592,000 -39% 01 Oct 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q3 2025 $28,516,000 $4,861,000 -$6,904,000 -59% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $35,420,000 $7,154,000 -$2,476,000 -26% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $37,896,000 $7,381,000 -$3,600,000 -33% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $41,496,000 $9,120,000 -$355,000 -3.7% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q3 2024 $41,851,000 $11,765,000 +$1,661,000 +16% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $40,190,000 $9,630,000 -$3,267,000 -25% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $43,457,000 $10,981,000 -$2,000 -0.02% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $43,459,000 $9,475,000 -$9,917,000 -51% 01 Oct 2023 31 Dec 2023 10-K 05 Mar 2025 2024 FY
Q3 2023 $53,376,000 $10,104,000 -$9,364,000 -48% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $62,740,000 $12,897,000 -$7,645,000 -37% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $70,385,000 $10,983,000 -$8,348,000 -43% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $78,733,000 $19,392,000 +$4,798,000 +33% 01 Oct 2022 31 Dec 2022 10-K 26 Feb 2024 2023 FY
Q3 2022 $73,935,000 $19,468,000 +$5,928,000 +44% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $68,007,000 $20,542,000 +$7,288,000 +55% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $60,719,000 $19,331,000 +$6,355,000 +49% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q4 2021 $54,364,000 $14,594,000 +$5,833,000 +67% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q3 2021 $48,531,000 $13,540,000 +$5,697,000 +73% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $42,834,000 $13,254,000 +$6,018,000 +83% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $36,816,000 $12,976,000 +$6,063,000 +88% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $30,753,000 $8,761,000 +$4,178,000 +91% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $26,575,000 $7,843,000 +$3,270,000 +72% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $23,305,000 $7,236,000 +$2,850,000 +65% 01 Apr 2020 30 Jun 2020 10-Q 04 Aug 2021 2021 Q2
Q1 2020 $20,455,000 $6,913,000 +$3,045,000 +79% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $17,410,000 $4,583,000 +$2,799,000 +157% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $14,611,000 $4,573,000 +$2,931,000 +179% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $11,680,000 $4,386,000 +$2,901,000 +195% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $8,779,000 $3,868,000 +$2,486,000 +180% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $6,293,000 $1,784,000 +$889,000 +99% 01 Oct 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
Q3 2018 $5,404,000 $1,642,000 +$771,000 +89% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $4,633,000 $1,485,000 +$512,000 +53% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $4,121,000 $1,382,000 +$515,000 +59% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $3,606,000 $895,000 +$77,000 +9.4% 01 Oct 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
Q3 2017 $3,529,000 $871,000 +$88,000 +11% 01 Jul 2017 30 Sep 2017 10-Q 01 Nov 2018 2018 Q3
Q2 2017 $3,441,000 $973,000 +$187,000 +24% 01 Apr 2017 30 Jun 2017 10-Q 06 Aug 2018 2018 Q2
Q1 2017 $3,254,000 $867,000 +$70,000 +8.8% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $3,184,000 $818,000 +$338,000 +70% 01 Oct 2016 31 Dec 2016 10-K 05 Mar 2019 2018 FY
Q3 2016 $2,846,000 $783,000 +$209,000 +36% 01 Jul 2016 30 Sep 2016 10-Q 01 Nov 2017 2017 Q3
Q2 2016 $2,637,000 $786,000 +$48,000 +6.5% 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017 2017 Q2
Q1 2016 $2,589,000 $797,000 +$189,000 +31% 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017 2017 Q1
Q4 2015 $2,400,000 $480,000 -$132,000 -22% 01 Oct 2015 31 Dec 2015 10-K 05 Mar 2018 2017 FY
Q3 2015 $2,532,000 $574,000 +$47,000 +8.9% 01 Jul 2015 30 Sep 2015 10-Q 07 Nov 2016 2016 Q3
Q2 2015 $2,485,000 $738,000 +$314,000 +74% 01 Apr 2015 30 Jun 2015 10-Q 08 Aug 2016 2016 Q2
Q1 2015 $2,171,000 $608,000 -$263,000 -30% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016 2016 Q1
Q4 2014 $2,434,000 $612,000 +$227,000 +59% 01 Oct 2014 31 Dec 2014 10-K 16 Mar 2017 2016 FY
Q3 2014 $2,207,000 $527,000 -$455,000 -46% 01 Jul 2014 30 Sep 2014 10-Q 03 Nov 2015 2015 Q3
Q2 2014 $2,662,000 $424,000 +$312,000 +279% 01 Apr 2014 30 Jun 2014 10-Q 05 Aug 2015 2015 Q2
Q1 2014 $2,350,000 $871,000 +$796,000 +1061% 01 Jan 2014 31 Mar 2014 10-Q 07 May 2015 2015 Q1
Q4 2013 $1,554,000 $385,000 01 Oct 2013 31 Dec 2013 10-K 03 Mar 2016 2015 FY
Q3 2013 $982,000 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014 2014 Q3
Q2 2013 $112,000 01 Apr 2013 30 Jun 2013 10-Q 12 Aug 2014 2014 Q2
Q1 2013 $75,000 01 Jan 2013 31 Mar 2013 10-Q 13 May 2014 2014 Q1

FATE THERAPEUTICS INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $24,924,000 -$16,572,000 -40% 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
2024 $41,496,000 -$1,963,000 -4.5% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
2023 $43,459,000 -$35,274,000 -45% 01 Jan 2023 31 Dec 2023 10-K 05 Mar 2025 2024 FY
2022 $78,733,000 +$24,369,000 +45% 01 Jan 2022 31 Dec 2022 10-K 26 Feb 2024 2023 FY
2021 $54,364,000 +$23,611,000 +77% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2023 2022 FY
2020 $30,753,000 +$13,343,000 +77% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $17,410,000 +$11,117,000 +177% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $6,293,000 +$2,687,000 +75% 01 Jan 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
2017 $3,606,000 +$422,000 +13% 01 Jan 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
2016 $3,184,000 +$784,000 +33% 01 Jan 2016 31 Dec 2016 10-K 05 Mar 2019 2018 FY
2015 $2,400,000 -$34,000 -1.4% 01 Jan 2015 31 Dec 2015 10-K 05 Mar 2018 2017 FY
2014 $2,434,000 +$880,000 +57% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2017 2016 FY
2013 $1,554,000 +$1,399,000 +903% 01 Jan 2013 31 Dec 2013 10-K 03 Mar 2016 2015 FY
2012 $155,000 -$17,000 -9.9% 01 Jan 2012 31 Dec 2012 10-K 12 Mar 2015 2014 FY
2011 $172,000 01 Jan 2011 31 Dec 2011 10-K 17 Mar 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.